中文摘要

中文摘要

目的： 通过观察裴氏软肝消痞丸(PRGXP)对小鼠H22瘤组织Ang-2的表达及血清IL-12含量的影响，以肿瘤血管的生成为研究点，探讨裴氏软肝消痞丸对肿瘤血管生成的抑制作用，以及对小鼠的免疫调节，为其抗肿瘤提供了理论依据。

方法： 按照随机原则将72只小鼠平均分为6组，每组12只，分别为A空白组、B对照模型组、C裴氏软肝消痞丸小剂量组、D裴氏软肝消痞丸中剂量组、E裴氏软肝消痞丸大剂量组、F复方斑蝥胶囊组。通过小鼠右前腋皮下接种瘤组织，为B-F组建立荷H22（肝癌）实体瘤小鼠模型，连续灌胃12d，停药24h后小鼠称重，眼球取血法采血于干净试管，离心后收集好血清在-20℃冰箱保存。小鼠脱臼处死后，剥离瘤组织、胸腺、脾脏进行称重，计算抑瘤率，免疫器官（脾脏、胸腺）指数，制作小鼠肝癌细胞切片，进行HE染色，观察病理变化；采用免疫组化法测定荷瘤小鼠瘤组织中Ang-2的表达，用ELISA法测定荷瘤小鼠血清IL-12的浓度。

结果：

1. 裴氏软肝消痞丸的各剂量组对荷瘤小鼠肿瘤组织均有抑制作用：大剂量组瘤重是(0.914±0.073)g，抑瘤率32.2%，中剂量组瘤重是(0.777±0.084)g，抑瘤率42.4%，小剂量组瘤重是(0.966±0.079)g，抑瘤率28.2%，瘤重均明显低于模型对照组，与对照组相比具有统计学意义(p<0.05)；

2. HE染色所示：裴氏软肝消痞丸各剂量组较模型对照组肿瘤细胞的坏死都有增多；

3. PRGXP各剂量组的胸腺指数TI、脾脏指数SI，均高于模型组，中剂量组的TI是(52.8±11.6)mg/10g，SI是(64.1±7.8)mg/10g，比较模型对照组具有统计学意义(p<0.05)；

4. 裴氏软肝消痞丸各剂量组的血清IL-12含量较模型对照组均升高，大、中剂量的IL-12含量分别为(20.95±3.58)pg/ml、(21.15±3.33)pg/ml，与模型组比较具有统计学意义(p<0.05)；复方斑蝥胶囊组(BM)血清中的浓度为(21.04±3.70)pg/ml，与模型对照组比较有统计学意义(p<0.05)；

5. 裴氏软肝消痞丸各剂量组的肿瘤组织Ang-2阳性细胞数的表达，均低于模型组，其中大、中剂量组与模型组比较有显著性差异(p<0.05)。

裴正学系列方药的研究

结论

裴氏软肝消痞丸对H₂₂荷瘤小鼠的肿瘤有明显的抑制作用，能够提升机体的非特异性的免疫功能，小鼠的胸腺、脾脏指数都相应增加。该药对H₂₂荷瘤小鼠瘤组织中的Ang-2的表达有抑制作用，同时升高了血清中IL-12含量，提示了裴氏软肝消痞丸抗肿瘤的作用之一可能是抑制了肿瘤血管的生成，从而抑制肿瘤的生长。

关键词： 裴氏软肝消痞丸；H₂₂（肝癌）；血管生成素2（Ang-2）；白介素12（IL-12）；血管生成

---

ABSTRACT

Objective: By observing the effect of Peishiruanganxiaopi pills (PRGXP) on the expression of Ang-2 in tumor and IL-12 in serum on H₂₂ bearing mice, in order to research the tumor angiogenesis, we have discussed Peishiruanganxiaopi Pill on tumor angiogenesis inhibition, as well as regulating on the immune system of tumor-bearing mice, and provide a scientific basis for the anti-tumor effects of the drug.

Methods: According to the principle of randomization, 72 of tumor-bearing mice model was divided into six groups, each group 12. Group A: blank group, and group B: model group, group C: little dose group of PRGXP, group D: middle dose group of PRGXP, group E: great dose group of PRGXP, group F: Fufang Banmao capsule (BM) group. By hypodermic inoculation in the right front axilla of mice, we established the tumor-bearing mice model for H₂₂. Every group was dosed for twelve days. After 24h of the last dose, the eyeballs of the mice were extirpated for blood collection with clean test tube, collected after centrifugation serum in -20°C refrigerator. Mice were killed after peeling tumor tissue, thymus, spleen weighing, calculating the tumor inhibiting rates, the thymus index (TI) and the spleen index (SI), make the slide of the H₂₂ tumor from the mice and to observe by HE technique; then we assessed effects of PRGXP on Ang-2 in tumor by immunohistochemistry method. Detected the concentration of IL-12 in serum by ELISA.

Results:

1. Each dose group of PRGXP on H₂₂ tumor-bearing mice showed significant inhibition of tumor weight. The weight of tumor in E, D and C group separately are (0.914±0.073) g, (0.777±0.084) g, (0.966±0.079) g, which lower than the model group (p<0.05), corresponding to the antitumor rate are 32.2%, 42.4% and 28.2%;
2. HE staining showed: There was more necrosis in each dose group of PRGXP than in the model group;
3. The SI and TI of the each dose group of PRGXP are higher than the model group. The SI and TI of the middle group are (52.8±11.6) mg/10g, (64.1±7.8) mg/10g, compared with the model group, there was a significantly difference (p<0.05);
4. The density of the IL-12 in each dose group of PRGXP are higher than the model group, the density of the IL-12 of the middle and great group separately are (21.15±3.33) pg·ml⁻¹, (20.95±3.58) pg·ml⁻¹, which has statistic significance in compare with the model group (p<0.05).
5. The expression of Ang-2 in tumor on PRGXP each dose groups have less than the model group.

裴正学系列方药的研究

PRGXP great and middle-dose group compared with the model group were significantly different (p<0.05).

Conclusion: Each dose group of Peishiruanganxiaopiwan (PRGXP) on H22 tumor-bearing mice showed significant inhibition of tumor weight. PRGXP can improve the body's non-specific immune function, increase the weight of spleen and thymus in mice. PRGXP inhibit the expression of Ang-2 in H22 tumor-bearing mice, while elevated serum IL-12 content. PRGXP anti-tumor effect maybe one of the mechanisms by inhibiting the expression of artery.

KEY WORDS: Peishiruanganxiaopiwan; H22 (transplanted liver cancer); Ang-2; IL-12; Angiogenesis.

---

前言